SWTX
SpringWorks Therapeutics Inc
Halal Rating :
Last Price
$34.65
Last updated:
Market Cap
-
7D Change
-6.38%
1 Year Change
-14.38%
Company Overview
Industries
Exchange
Next Earnings Date
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's lead product candidates include nirogacestat for the treatment of desmoid tumors and mirdametinib for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $49.3m | $107.24m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $59.73m | $104.65m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $21.01m | $114.94m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate SpringWorks Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.